MedPath
HSA Approval

SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG

SIN16958P

SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG

SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG

February 20, 2024

ASTRAZENECA SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantASTRAZENECA SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

A10BD29

sitagliptin and dapagliflozin

Manufacturer Information

ASTRAZENECA SINGAPORE PTE LTD

SK Chemicals Co, Ltd (1346)

Active Ingredients

Dapagliflozin propanediol monohydrate eqv Dapagliflozin

10mg

Dapagliflozin

Sitagliptin phosphate monohydrate eqv Sitagliptin

100mg

Sitagliptin

Documents

Package Inserts

Sidapvia tablet PI.pdf

Approved: February 20, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.